https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-15T12:00:00.000Z Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026 https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ivonescimab-update BiopharmaWatch en 2026-11-15T12:00:00.000Z Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-business-update-q3-2026 BiopharmaWatch en 2026-11-15T12:00:00.000Z Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LLY/lilly-obesityweek-2026-data-presentation BiopharmaWatch en 2026-11-14T17:01:00.000Z Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale https://www.biopharmawatch.com/news/AMLX/amylyx-avexitide-phase-3-results-obesityweek-2026 BiopharmaWatch en 2026-11-14T17:00:00.000Z Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting https://www.biopharmawatch.com/news/WWB/windward-bio-nasdaq-ipo BiopharmaWatch en 2026-11-14T15:57:00.000Z Innovative Immunology Biotech Windward Bio Lists on Nasdaq https://www.biopharmawatch.com/news/ZLAB/zai-lab-2026-nrdl-inclusion-karxt-vyvgart BiopharmaWatch en 2026-11-14T03:26:00.000Z Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products https://www.biopharmawatch.com/news/VVVV/nyse-welcomes-vvardis-publicly-listed-company BiopharmaWatch en 2026-11-13T22:56:00.000Z The NYSE Welcomes vVARDIS as a Publicly Listed Company https://www.biopharmawatch.com/news/CNSY/cerenome-q3-2026-results-reyobiq-progress BiopharmaWatch en 2026-11-13T22:19:00.000Z Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress https://www.biopharmawatch.com/news/BYSI/beyondspring-third-quarter-2026-results-update BiopharmaWatch en 2026-11-13T22:15:00.000Z BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IMCC/im-cannabis-corp-q3-2026-financial-results BiopharmaWatch en 2026-11-13T22:10:00.000Z IM Cannabis Corp. Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARAY/accuray-tcw-transaction-strengthening-balance-sheet BiopharmaWatch en 2026-11-13T22:10:00.000Z Accuray Closes TCW Transaction, Strengthening Balance Sheet to Support Long-Term Value Growth https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q3-2026-results BiopharmaWatch en 2026-11-13T22:03:00.000Z Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/TPST/tempest-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-13T21:47:00.000Z Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CING/cingulate-reports-q3-2026-results-ctx-1301-update BiopharmaWatch en 2026-11-13T21:45:00.000Z Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission https://www.biopharmawatch.com/news/ZLAB/zai-lab-investor-conferences-november-2026 BiopharmaWatch en 2026-11-13T21:35:00.000Z Zai Lab Announces Participation in Investor Conferences in November 2026 https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-ubs-ceo-call-2026 BiopharmaWatch en 2026-11-13T21:30:00.000Z Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026 https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-fiscal-2027-q1-results BiopharmaWatch en 2026-11-13T21:30:00.000Z Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results https://www.biopharmawatch.com/news/ASTC/astrotech-fiscal-year-2027-financial-results BiopharmaWatch en 2026-11-13T21:20:29.000Z ASTROTECH REPORTS FIRST QUARTER OF FISCAL YEAR 2027 FINANCIAL RESULTS https://www.biopharmawatch.com/news/MEDS/datameds-ai-reports-revenue-growth-q3-2026 BiopharmaWatch en 2026-11-13T21:15:45.000Z DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-nasdaq-listing-rule-20261113 BiopharmaWatch en 2026-11-13T21:15:00.000Z Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/EOLS/evolus-reports-inducement-grants-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-13T21:05:00.000Z Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GH/guardant-health-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-13T21:05:00.000Z Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-13T21:05:00.000Z Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-q3-2026-financial-results BiopharmaWatch en 2026-11-13T21:05:00.000Z TherapeuticsMD Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FEMY/femasys-financial-results-q3-2026-update BiopharmaWatch en 2026-11-13T21:05:00.000Z Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-20261113 BiopharmaWatch en 2026-11-13T21:05:00.000Z 4DMT Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-13T21:05:00.000Z Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/VTGN/vistagen-fiscal-year-2027-q2-results-update BiopharmaWatch en 2026-11-13T21:05:00.000Z Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KRRO/korro-bio-stock-option-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-11-13T21:05:00.000Z Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/OCS/oculis-notifications-transactions-managerial-responsibilities BiopharmaWatch en 2026-11-13T21:05:00.000Z Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities https://www.biopharmawatch.com/news/INBX/inhibrx-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-13T21:02:00.000Z Inhibrx Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TRXB/trexbio-reports-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-13T21:02:00.000Z TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/NVS/novartis-cosentyx-chmp-opinion-hidradenitis-suppurativa BiopharmaWatch en 2026-11-13T18:30:00.000Z Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS) https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conferences-november-2026 BiopharmaWatch en 2026-11-13T17:33:00.000Z Kura Oncology to Participate in Two Investor Conferences in November https://www.biopharmawatch.com/news/PNTG/pennant-group-2026-stephens-investment-conference BiopharmaWatch en 2026-11-13T17:25:00.000Z Pennant Group to Participate in the 2026 Stephens Annual Investment Conference https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-clinical-supply-agreement-evaluate-pelareorep-combination BiopharmaWatch en 2026-11-13T17:10:00.000Z Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC https://www.biopharmawatch.com/news/XRTX/xortx-patent-allowed-japan-patent-office BiopharmaWatch en 2026-11-13T17:00:00.000Z XORTX Patent Allowed for XRx-101 Program by Japan Patent Office https://www.biopharmawatch.com/news/NVO/frehemgo-denecimig-eu-approval-haemophilia-a BiopharmaWatch en 2026-11-13T16:46:00.000Z FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing https://www.biopharmawatch.com/news/NVCR/jama-network-open-publishes-panova-3-trial-data BiopharmaWatch en 2026-11-13T16:30:00.000Z JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer https://www.biopharmawatch.com/news/LFWD/lifeward-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-13T14:16:00.000Z Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-strong-cash-asset-position BiopharmaWatch en 2026-11-13T14:15:00.000Z PharmaCyte Biotech Reports Strong Cash and Asset Position https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-13T14:04:00.000Z Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/JAGX/jaguar-health-investor-webcast-november-2026 BiopharmaWatch en 2026-11-13T14:00:00.000Z Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-atopic-dermatitis-infants-acaaimeeting BiopharmaWatch en 2026-11-13T14:00:00.000Z Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-drug-programs-sno-fda-meetings BiopharmaWatch en 2026-11-13T13:52:00.000Z NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach https://www.biopharmawatch.com/news/MTVA/metavia-reports-q3-2026-results-corporate-update BiopharmaWatch en 2026-11-13T13:31:00.000Z MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/AGPU/axe-compute-appoints-guang-yang-board BiopharmaWatch en 2026-11-13T13:30:15.000Z Axe Compute Appoints Guang Yang to Board of Directors https://www.biopharmawatch.com/news/SSII/ss-innovations-management-team-global-expansion BiopharmaWatch en 2026-11-13T13:30:00.000Z SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-priority-voucher-impact BiopharmaWatch en 2026-11-13T13:30:00.000Z OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-13T13:30:00.000Z Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates https://www.biopharmawatch.com/news/TNDM/tandem-mobi-fda-cleared-tubeless-aid-system BiopharmaWatch en 2026-11-13T13:30:00.000Z Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-2-pancreatic-cancer-data-2027 BiopharmaWatch en 2026-11-13T13:30:00.000Z AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KYNB/kyntra-bio-third-quarter-2026-results BiopharmaWatch en 2026-11-13T13:30:00.000Z Kyntra Bio to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/WVE/wave-life-sciences-wve-007-obesityweek-2026 BiopharmaWatch en 2026-11-13T13:30:00.000Z Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026 https://www.biopharmawatch.com/news/VCEL/vericel-presentation-stephens-investment-conference-2026 BiopharmaWatch en 2026-11-13T13:30:00.000Z Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026 https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-375-million-public-offering BiopharmaWatch en 2026-11-13T13:12:00.000Z InspireMD Announces Pricing of $37.5 Million Public Offering https://www.biopharmawatch.com/news/NNOX/nanox-distribution-agreement-medworks-greece BiopharmaWatch en 2026-11-13T13:10:00.000Z Nanox Announces Distribution Agreement with Medworks for Nanox.AI in Greece https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-13T13:05:00.000Z Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/BFRI/biofrontera-q3-2026-financial-results BiopharmaWatch en 2026-11-13T13:02:00.000Z Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth https://www.biopharmawatch.com/news/RVTY/revvity-2026-investor-day-strategy BiopharmaWatch en 2026-11-13T13:00:00.000Z Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-q3-2026-results BiopharmaWatch en 2026-11-13T13:00:00.000Z PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GHRS/gh-research-q3-2026-financial-results-update BiopharmaWatch en 2026-11-13T13:00:00.000Z GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SRZN/surrozen-announces-60-million-offering-common-stock BiopharmaWatch en 2026-11-13T13:00:00.000Z Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock https://www.biopharmawatch.com/news/PDSB/pds-biotech-third-quarter-2026-results BiopharmaWatch en 2026-11-13T13:00:00.000Z PDS Biotech Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IRLA/irulya-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-13T13:00:00.000Z IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-13T13:00:00.000Z Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/FBIO/fortress-biotech-q3-2026-financial-results BiopharmaWatch en 2026-11-13T13:00:00.000Z Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-q1-2027-financial-results-update BiopharmaWatch en 2026-11-13T13:00:00.000Z Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-q3-2026-results BiopharmaWatch en 2026-11-13T13:00:00.000Z Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-11-13T13:00:00.000Z Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/GHRS/gh-research-appoints-vanina-popova-cdo BiopharmaWatch en 2026-11-13T12:55:00.000Z GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-q3-2026-financial-results-update BiopharmaWatch en 2026-11-13T12:45:00.000Z TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update